What is it about?
This post-doc analysis looked at the impact of Beta-Blockers on patients receiving Aclidinium bromide 400 µg (LAMA) to reduce symptoms of COPD. All participants had moderate-to-very severe COPD and at least one CV risk factor. The Aclidinium bromide treatment reduced moderate-to-severe COPD exacerbations in both beta-blocker users and non-users. The beta-blocker group with not have an increased risk of MACE when treated with aclidinium versus placebo.
Featured Image
Photo by Hannah Busing on Unsplash
Why is it important?
CV and cerebrovascular comorbidities are common in patients with COPD. Beta-blockers are often withheld in patients with COPD over concerns of worsening airway obstruction and there is hesitation in prescribing LAMA for those with CV. But aclidinium did not increase MACE and improved COPD outcomes demonstrating the safety and efficacy of concurrent treatment.
Perspectives
Providing holistic person-centred care means recognizing all of a patient's co-morbidities. The results from this study help to show that therapies once considered antagonists can work synergically to help control COPD without increasing one risk for a CV event.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers, October 2021, Springer Science + Business Media,
DOI: 10.1186/s12931-021-01861-2.
You can read the full text:
Resources
Contributors
The following have contributed to this page
